ArticleInternal medicine (Tokyo, Japan)2023
Prophylactic Treatment for Patients with Migraine Using Blue Cut for Night Glass.
Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Assessing the relationships between migraine and driving risks, challenges and coping strategies.Scientific reports · 2026Article
- Colorimetric and Photobiological Properties of Light Transmitted Through Low-Vision Filters: Simulated Potential Impact on ipRGCs Responses Considering Crystalline Lens Aging.Life (Basel, Switzerland) · 2025Article
- Hypersensitivity of Intrinsically Photosensitive Retinal Ganglion Cells in Migraine Induces Cortical Spreading Depression.International journal of molecular sciences · 2024Article
- Light Therapy in Chronic Migraine.Current pain and headache reports · 2024Review
- Preliminary External Validation Results of the Artificial Intelligence-Based Headache Diagnostic Model: A Multicenter Prospective Observational Study.Life (Basel, Switzerland) · 2024Article
- Headache Education by E-Learning Through Social Networking Services (Social Media).Journal of healthcare leadership · 2023Article
- Connection between right-to-left shunt and photosensitivity: a community-based cross-sectional study.Frontiers in neurology · 2023Article
- Blue-light-filtering spectacle lenses in managing vision-related symptoms: an updated review.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives Migraine is a disease that leads to social loss due to a decrease in productivity since it is a primary headache with a high prevalence and readily occurs in working-age persons. As described in the diagnostic criteria of the International Classification of Headache Disorders, 3rd edition (beta version), migraine causes hypersensitivity, especially photosensitivity, during attacks, suggesting that light is an inducer of headaches. We developed Blue Cut for Night (BCN) glass, which reduces light stimulation to intrinsically photosensitive continental ganglion cells (ipRGCs), photoreceptors that can lead to exacerbation of migraine attacks. Methods Ten patients with migraine participated in the study. Each participant was made to wear BCN glasses only at night for four weeks. The number of headache days and Headache Impact Test-6 values before and after using the BCN glasses were compared. Results When the 10 patients with migraine wore the BCN glass at night only for 4 weeks, the number of headache days within that time tended to decrease (7.0±4.37 days) compared to before wearing the glasses (8.7±5.03 days). No participants had any side effects. Conclusion BCN glass, which reduces light stimulation to ipRGCs, was suggested to be a tool for reducing migraine attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.